hodgkin's%20lymphoma
HODGKIN'S LYMPHOMA

Hodgkin's lymphoma is a malignancy that arises from germinal center B cell.

Histologically, there is a presence of multinucleated giant cells in a mixed inflammatory background.

It is also known as Hodgkin's disease, Hodgkin lymphoma or Hodgkin disease.

It commonly affects individuals ages 15-30 years old and those 55 years old and above.

The key morphologic characteristics include presence of Reed-Sternberg cells and lymphocyte-predominant cells.

Hodgkin's Lymphoma Drug Information

Drug Information

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: Monotherapy in patients w/ chronic lymphocytic leukaemia; indolent B-cell non-Hodgkin's lymphomas that has pro...

Indication: Adult patients w/ relapsed or refractory CD30+ Hodgkin lymphoma (HL) following autologous stem cell transplant...

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Alone or in combination w/ other chemotherapeutic agents for induction of leukaemia remission, particularly fo...

Indication: Monotherapy or in combination w/ other chemotherapeutic agents for metastatic non-seminomatous germ cell carci...

Indication: Induction & maintenance of remission in acute myelocytic leukaemia in adult & childn. Other leukemias ...

Indication: Squamous cell carcinoma of skin, head, neck & oesophagus, larynx, penis & uterine cervix, bronchus. Ch...

Indication: Monotherapy or combination therapy for palliative treatment of metastatic non-seminomatous germ cell carcinoma...

Indication: Alone or in combination w/ other chemotherapeutic agents for induction of remission of acute myeloid leukaemia...

1  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.